NCT07745426 Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis
| NCT ID | NCT07745426 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Tanta University |
| Condition | Rheumatoid Arthritis (RA) |
| Study Type | INTERVENTIONAL |
| Enrollment | 66 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 66 participants in total. It began in 2026-08-01 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will be a randomized controlled parallel study that will be conducted on 66 patients with active rheumatoid arthritis who will be diagnosed with RA according to American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR, 2010). The patients will be recruited from Outpatient Clinic of Rheumatology, Physical Medicine, Rheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt. The study duration will be 3 months. The patients will be randomized into three groups: \- Group 1 (control group): will include 22 patients who will receive the conventional therapy for RA for 3 months. \- Group 2 (diosmin group): will include 22 patients who will receive the conventional therapy for RA plus 1000 mg diosmin once daily for 3 months. \- Group 3 (rebamipide group): will include 22 patients who will receive the conventional therapy for RA plus 100 mg rebamipide three times daily for 3 months.
Eligibility Criteria
Inclusion Criteria: * Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR). i.e.,28 joints disease activity score (DAS-28) \>2.6. * Both sexes. * Age ranges between 18 and 70 years old. * Patients receiving conventional DMARDs Exclusion Criteria: * Pregnant and lactating females. * Patients receiving biological DMARDs or targeted synthetic DMARDs. * Patients with renal and hepatic dysfunction. * Patients with other inflammatory/autoimmune diseases, active infection, or malignancies. * Patients with bleeding disorders, receiving warfarin or other anticoagulants. * Patients receiving antioxidants. * Patients with hypersensitivity to study medications.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07745426 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Rheumatoid Arthritis (RA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07745426 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07745426 currently recruiting?
Yes, NCT07745426 is actively recruiting participants. Contact the research team at khlood.kettana@pharm.tanta.edu.eg for enrollment information.
Where is the NCT07745426 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT07745426 clinical trial?
NCT07745426 is sponsored by Tanta University. The trial plans to enroll 66 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.